Log In

Forgot Password?
Create New Account

Loading... please wait

2024 Annual Meeting | H223 - Not Red, Not Blue, Just #AAN Green: How AAN Advocacy Overcomes the Partisan Divide from Policy Development to BrainPAC (Practice and Policy Hub)

Wednesday 04/17/24
01:30 PM - 02:30 PM MDT Add To Calendar
Colorado Convention Center | Lobby F
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Hubs (Practice and Policy)
Christine D. Esper, MD, FANA, FAAN, Nina Y. Riggins, MD, FAAN
Practice, Policy, and Ethics
 
Participants should be able to list the various mechanisms and programs available through AAN to support neurology, describe how the academy forms official academy policy positions, identify the role of BrainPac in AAN Advocacy, and define ways BrainPac supports wins for each neurologist and a future of neurology  
1.00 CME credit
Interpersonal and Communication Skills, Systems-based Practice, Quality Improvement
Introductory
Brain Health
Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student, Business Administrator
Case-based, Audience Participation

Program Materials Program Evaluations

Event Timeline
01:30 PM - 02:30 PM MDT Speaker Not Red, Not Blue, Just #AAN Green: How AAN Advocacy Overcomes the Partisan Divide from Policy Development to BrainPac
Christine D. Esper, MD, FANA, FAAN, Nina Y. Riggins, MD, FAAN
Faculty Disclosures
Christine D. Esper, MD, FANA, FAAN Dr. Esper has received research support from Centers for Disease Control and Prevention. Dr. Esper has received publishing royalties from a publication relating to health care.
Nina Y. Riggins, MD, FAAN Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Gerson Lehrman Group . Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. The institution of Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. The institution of Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amneal Pharmaceuticals. Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NeurologyLive. The institution of Dr. Riggins has received research support from ElectroCore (GammaCore). The institution of Dr. Riggins has received research support from Miles for Migraine. The institution of Dr. Riggins has received research support from Eli Lilly. Dr. Riggins has received publishing royalties from a publication relating to health care. Dr. Riggins has received publishing royalties from a publication relating to health care. Dr. Riggins has received publishing royalties from a publication relating to health care. Dr. Riggins has a non-compensated relationship as a PI on research study with TheraSpecs that is relevant to AAN interests or activities. Dr. Riggins has a non-compensated relationship as a Advisory Board with NeurologyLive that is relevant to AAN interests or activities. Dr. Riggins has a non-compensated relationship as a Member of the Board with Miles for Migraine that is relevant to AAN interests or activities. Dr. Riggins has a non-compensated relationship as a PI in the study which used sphenocath device with Dolor Technologies that is relevant to AAN interests or activities. Dr. Riggins has a non-compensated relationship as a PI with Theranica that is relevant to AAN interests or activities.